Metadata record for the article: Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial
Abstract
Summary This metadata record provides details of the data supporting the claims of the related article: “Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial”. The related study examined metformin impact on metabolic factors in non-diabetic subjects to determine whether this impact varies by baseline BMI, insulin and rs11212617 SNP in CCTG MA.32, a double-blind placebo controlled randomised adjuvant breast cancer (BC) trial. Type of data: single-nucleotide polymorphism (SNP); clinical data Subject of data: Homo sapiens Sample size: 2915 Population characteristics: See Table 1 of the related article Trial registration number: http://clinicaltrials.gov/show/NCT01101438 Data access The SNP data are openly available as part of this figshare metadata record in the file ‘MA32_snp_data.csv’. The primary efficacy analysis will be available from the Canadian Cancer Trials Group (Kingston, Ontario) after the results of the analysis have been published. These data will be uploaded to the NCI data archive website: https://nctn-data-archive.nci.nih.gov/view-trials and will be searchable via NCT trial number NCT01101438. As of April 2021, the group is working towards this publication. Further details can be requested from the corresponding author. The clinical data are not publicly available for the following reason: data contain information that could compromise research participant privacy. Corresponding author(s) for this study…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.